Oral Communications 2

ea0023oc2.1 | Oral Communications 2 | BSPED2009

Final height in Turner syndrome after Oxandrolone and delayed pubertal induction: results of a UK randomised, double-blind, placebo-controlled trial

Gault Emma-Jane , Perry Rebecca , Casey Sarah , Cole Tim , Paterson Wendy , Hindmarsh Peter , Betts Peter , Dunger David , Donaldson Malcolm

The UK Turner Study examined in girls with Turner syndrome (TS) the impact on final height (FH) of Oxandrolone (Ox) and/or delayed pubertal induction (14y).Methods: Girls with TS aged 713y receiving GH were randomised to Ox (0.05 mg/kg per day, max. dose 2.5 mg/day) or placebo from 9y (or from enrolment if >9y). Girls requiring oestrogen were further randomised to begin oral Ethinylestradiol (E2) (Y1:2 μg/day; Y2:4 μg/day; ...

0 shares

ea0023oc2.2 | Oral Communications 2 | BSPED2009

Recombinant human GH improves linear growth in children with inflammatory bowel disease: results of a randomised controlled trial

Wong S C , Kumar P , Casson D H , Dalzell A M , Blair J C , Didi M , Hassan K , McGrogan P , Ahmed S F

Background: Despite optimal management, children with inflammatory bowel disease (IBD) may suffer from growth retardation. The role of rhGH in these children is unclear.Design: Randomised controlled trial of rhGH (0.067 mg/kg per day) for 6 months.Subjects: Twenty-two children with IBD and HtSDS<−2 or HtSDS<−1 and HVSDS<−1. Eleven were in the control group (C) and eleven in the treatment group (Rx).</p...

0 shares

Endocrine Abstracts

37th Meeting of the British Society for Paediatric Endocrinology and Diabetes

Oral Communications

Final height in Turner syndrome after Oxandrolone and delayed pubertal induction: results of a UK randomised, double-blind, placebo-controlled trial

Recombinant human GH improves linear growth in children with inflammatory bowel disease: results of a randomised controlled trial

BiosciAbstracts